Prediction of dose reductions and impact of reduced starting doses of CDK4 /6i on effectiveness in HR ‐positive/ HER2 ‐negative metastatic breast cancer: Real‐world data from the OPAL registry

Documenti analoghi

• Head‐to‐head comparison of palbociclib and ribociclib in first‐line treatment of HR‐positive/HER2‐negative metastatic breast cancer with real‐world data from the OPAL registry
  di: Marc Thill, et al.
  Pubblicazione: (2024)
• DE “COMUNIDADE” PARA “SOCIEDADE”: MEMÓRIA SOCIAL E LUTA POR AUTONOMIA NOS 50 ANOS DA REVOLTA DOS COLONOS NO SUDOESTE DO PARANÁ
  di: Walter Marschner
  Pubblicazione: (2008)
• Head‐to‐head comparison of TKI and CPI first‐line treatment strategies in advanced renal cell carcinoma—Real‐world data from the German research platform CARAT
  di: Peter J. Goebell, et al.
  Pubblicazione: (2025)
• Das neue Volk Gottes in Hispanien
  di: Marschner, Patrick Sebastian
  Pubblicazione: (2023)
• Como o volume de negociação reage ao sentimento do investidor?
  di: Paulo Fernando Marschner
  Pubblicazione: (2019)